Key facts
- WuXi Biologics completed the topping out of its Drug Product facility in Singapore.
- The Singapore CRDMO Hub will offer integrated drug development and manufacturing services.
- The topping out signifies a construction milestone for the facility.
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub. This milestone signifies a significant step in the construction of the facility, which is designed to provide comprehensive drug development and manufacturing services.